ArriVent BioPharma Reports Second Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2024
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC)
